Cure8 research brief
Cure8 research brief
The study points to LILRB3 as a tissue biomarker tied to proinflammatory macrophage changes in UC, which could help researchers understand disease mechanisms and guide future biomarker or therapeutic research.
Researchers in IBD immunology and biomarker discovery; clinicians involved in translational UC research; informed patients interested in emerging UC research.
This paper combined bulk transcriptomics, single-cell RNA-seq analyses, machine-learning feature selection, and experimental validation (mouse DSS colitis model, human UC tissue, and macrophage knockdown experiments).
The authors report that LILRB3 is enriched in myeloid cells—especially M1 macrophages—correlates with inflammatory cell infiltration and intercellular signaling, and that LILRB3 knockdown in THP-1-derived macrophages reduced expression of proinflammatory cytokine mRNAs.
This record is an abstract-level journal article combining bioinformatics and experimental validation. Findings are preliminary for clinical application and require additional mechanistic and clinical validation.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.